Log in
Development of the human cell GADD45a assay enabled accurate identification of carcinogens in vitro, with a low rate of misleading positives. Through the spin-out company Gentronix, this research is reducing costs to industry and decreasing the use of animals in research. Industrial collaboration has enabled commercial adoption of the technology in many sectors. With a 10-fold increase in orders in 2012 versus 2008, Gentronix is a profitable business employing 17 people and with an annual turnover of £1.88m. During 2008-12, Gentronix released a series of new products, established testing services, and signed a product license agreement with GlaxoSmithKline. More than 100 companies worldwide are using Gentronix kits, including pharmaceutical, agricultural and health and beauty companies, along with manufacturers of food flavourings and household goods. The Gentronix assay is currently being reviewed by the European Centre for the Validation of Alternative Methods.
Our research on Active Shape Models (ASMs) and Active Appearance Models (AAMs) opened up a radically new approach to automated image interpretation, with applications in industrial inspection, medical image analysis, and face tracking/recognition. We identify:
Measurement of hormones is essential to the understanding and diagnosis of endocrine diseases. White and her research group have developed unique antibodies that are widely used in diagnostic assays for adrenocorticotrophic hormone (ACTH) and related peptides, including the first and only kit for measuring pro-opiomelanocortin (POMC), the precursor of ACTH. These assays are used worldwide for diagnosis, decisions on treatment, monitoring for recurrence of tumours and prognosis in a number of patient groups with life-threatening endocrine disorders. Global sales of the ACTH Elecsys tests by Roche exceeded 6 million kits since 2008. AstraZeneca has used the POMC and ACTH assays in its drug discovery programmes in the cardiovascular and metabolic diseases therapy area. The antibodies therefore have had health impact in relieving suffering and in improving patient care, as well as commercial impact in worldwide sales of assays and influencing drug development strategies.
Research on ester liquids (ELs) has proved they can be used in high-voltage (HV) transformers, bringing economic and safety advantages to the power industry and environmental benefits to society. Impact includes revisions to National Grid's oil policy recommending ester-filled HV transformers for use in London and the design and operation of the first 132kV "green" transformer (valued between £1m and £2m). The research has led directly to the creation of two international standards for professionals in global power utilities specifying the use of ELs in transformers. These developments have contributed directly to Manchester SME M&I Materials increasing sales from £15m (2008) to £29m (2012).
Improving patient experience of health services is a policy priority worldwide. The University of Manchester (UoM) has conducted research on patient experience since 1995, leading to the development of a series of validated measures for assessing patient experience of quality of care in primary care, including access to care and the degree to which services are patient-centred. Our measures have been in routine use in the NHS since 2004, sent to samples of several million patients. The data have been used to provide incentives for the highest quality practices, and to inform policy makers about current care throughout the UK.
Tyndall-Manchester's research into UK aviation emissions was instrumental in overturning the prevailing orthodoxy, which regarded aviation as an unproblematic, small source of greenhouse gas emissions. Identifying drivers of growth and key characteristics of aviation's emerging emissions trajectory demonstrated that aviation could soon dominate national emissions if left unchecked. Tyndall-Manchester's research contributed to aviation's inclusion in sub-national, national and international climate policies. Specifically, it was highly influential in debates leading to including international aviation in the UK's 2050 emissions target; bringing aviation into the European Union's Emission Trading System. It continues to inform debate around future UK airport expansion, and is used to guide campaigning objectives of major environmental NGOs and lobby groups.
BRITEST is a global leader in the development of innovative process solutions for the chemical processing sector with > £500m of value being realized since 2008. Research in Manchester (1997-2000) generated a set of novel tools and methodologies which analyse chemical processes to identify where and how process improvements could be made. BRITEST was established in 2001 as a not-for-profit company to manage the technology transfer and effective deployment of these tools and methodologies into industry. Manchester holds the IP arising from the underpinning research and has granted an exclusive license to BRITEST for use and exploitation of the toolkit.
School dental screening was a statutory function of the NHS. University of Manchester (UoM) research demonstrated that the national screening programme was ineffective and likely to increase inequalities in health and service utilisation. As a direct result of UoM research, the National Screening Committee recommended that the national programme should stop. This changed Departments of Health policy resulting in new guidance to the NHS, which stopped the screening programme and redirected resources to treatment services for vulnerable groups and prevention programmes. In 2010 in England the costs of a national screening programme were estimated to be £17m per year; money released for reallocation to other dental services.
Urban greenspace cools cities and reduces rainfall runoff but these effects have been difficult to quantify. Ennos's research is the first to give realistic figures for the contribution of greenspace and assess its potential to climate-proof cities. Key research findings have furthered the concept of green infrastructure, influenced local and national planning policy [text removed for publication]. Novel mapping tools developed by Ennos have had international impact, including use in the city master plan for Addis Ababa, Ethiopia. Community forests have altered their planting practises as a result of Ennos's research findings.
Life-threatening bacterial endocarditis occurs on previously damaged cardiac valves. Established dental practice has been to administer antibiotics to patients who are at risk. This practice has been linked with increased antibiotic resistance, which represents one of the greatest threats to public health.
Researchers at the University of Manchester (UoM) evaluated the evidence for this practice by undertaking a high quality systematic review (initially published 2004). The review has informed multiple international guidelines. Publication of the NICE guideline led to a fall in the unnecessary prescription of antibiotics from 10,727 to 2,292 per month, an approximate annual saving of £174,580.